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Objectives We sought to evaluate the utility of the JOSTENT polytetraﬂuoroethylene (PTFE) stent-
graft (Jomed GmbH, Rangendingen, Germany) in patients with diseased saphenous vein grafts
(SVGs)
undergoing percutaneous coronary intervention (PCI).
Background Prior trials of the JOSTENT stent-graft did not mandate high-pressure implantation or
prolonged dual antiplatelet therapy, and were limited by short-term follow-up.
Methods A total of 243 patients at 47 centers with 1 to 2 discrete lesions in SVGs were prospec-
tively randomized to JOSTENT implantation (18 atm.) versus bare-metal stents (BMS). The JOSTENT
patients were treated with aspirin indeﬁnitely and clopidogrel for 8 months. Routine angiographic
ollow-up was performed at 8 months, and all patients were followed for 5 years.
esults The primary end point of in-lesion binary restenosis occurred in 31.8% of lesions treated
ith the JOSTENT versus 28.4% of lesions treated with BMS (relative risk: 1.12, 95% conﬁdence inter-
al [CI]: 0.72 to 1.75, p  0.63). At 9 months, the major secondary end point of target vessel failure
death, myocardial infarction, or clinically driven target vessel revascularization) occurred in 32.2% of
atients treated with the JOSTENT versus 22.1% of patients treated with BMS (hazard ratio: 1.54,
5% CI: 0.94 to 2.53, p  0.08). During long-term follow-up, signiﬁcantly more events accrued in the
JOSTENT arm such that by 5 years target vessel failure had occurred in 68.3% of JOSTENT patients
versus 51.8% of BMS patients (hazard ratio: 1.59, 95% CI: 1.13 to 2.23, p  0.007).
Conclusions The long-term prognosis for diseased SVGs requiring PCI is dismal. The JOSTENT PTFE
stent-graft results in inferior outcomes compared with BMS, despite high-pressure implantation and
prolonged dual antiplatelet therapy, a ﬁnding that becomes more evident with longer-term
follow-up. (J Am Coll Cardiol Intv 2011;4:300–9) © 2011 by the American College of Cardiology
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301As many as 25% to 30% of saphenous vein grafts (SVGs)
fail within 12 to 18 months after coronary artery bypass
graft surgery (CABG) (1), a proportion that increases to
50% beyond 10 years (2,3). Compared with treatment of
native coronary arteries, percutaneous coronary intervention
(PCI) of diseased SVGs is associated with higher rates of
periprocedural complications and an increased incidence of
clinical and angiographic restenosis (4,5). Distal protection
devices improve the procedural safety of PCI in SVGs (6,7),
whereas bare-metal stents (BMS) improve event-free sur-
vival compared with balloon angioplasty (8). Recently, 2
small randomized trials have provided conflicting results as
to whether drug-eluting stents (DES) further improve
outcomes after PCI of SVGs (9,10). Novel approaches are
needed to further improve the prognosis of diseased SVGs.
The JOSTENT stent-graft (Jomed GmbH, Rangendin-
gen, Germany) consists of a distensible polytetrafluoro-
ethylene (PTFE) membrane sandwiched between 2 316L
stainless steel slotted tube, balloon-expandable stents
(Fig. 1) (11). This device is currently available in the U.S. as the
raftMaster (Abbott Vascular, Santa Clara, California)
nder a Humanitarian Device Exemption for treatment of
ife-threatening coronary perforations (12). Hypothetical
enefits of elective use of the JOSTENT PTFE stent-graft
n SVGs include reduced periprocedural myocardial infarc-
ion (MI) (by trapping potentially embolic degenerated
therosclerotic debris behind the PTFE membrane) and
ecreased restenosis (by serving as a barrier isolating the
umen from smooth muscle cell proliferation, migration,
nd extracellular matrix production arising from the media)
13). After favorable results from a multicenter registry (14),
trials were performed in which the JOSTENT was
andomized to BMS in diseased SVGs, demonstrating
omparable or increased rates of MI, restenosis, and late
cclusion with the stent-graft (15,16). However, neither of
hese trials mandated high-pressure balloon inflation or
rolonged dual antiplatelet therapy, measures that might be
ecessary to mechanically optimize the implant and facili-
ate endothelialization without thrombosis. Moreover,
ollow-up was limited to only 6 and 12 months in these
tudies, precluding the opportunity to determine whether
here are late benefits (or harm) from this device—a salient
ssue, because the time course of both target lesion revas-
ularization (TLR) and target vessel revascularization
TVR) might be protracted in SVGs compared with native
oronary arteries (17).
Therefore, we performed a prospective, multicenter, ran-
omized, controlled trial termed BARRICADE (Barrier
pproach to Restenosis: Restrict Intima to Curtail Adverse
vents) to evaluate the utility of the JOSTENT PTFE
tent-graft for the treatment of discrete atherosclerotic
esions in diseased SVGs. JOSTENT post-dilation to 18
tm was mandated to overcome limitations of prior studies, ts was use of dual antiplatelet therapy for 8 months, and
ll patients were followed for a total duration of 5 years. The
resent report represents the principal and final analysis
rom the BARRICADE trial.
ethods
Enrollment criteria. To be eligible for the BARRICADE
rial, patients 18 years of age with clinical evidence of
schemia or a positive functional study had to have 1 or 2
VG lesions eligible for PCI with either both lesions in 1
VG or 1 lesion in each of 2 SVGs. Lesion eligibility
equired all the following to be present: visually estimated
iameter stenosis of 50% and 100%; target vessel
iameter 3.0 mm and 5.0
m; lesion length25 mm; and
hrombolysis In Myocardial In-
arction flow grade1 after suc-
essful wire passage. All patients
ad to agree to all follow-up
rocedures and provide informed,
ritten consent. Patients were
xcluded from randomization if
ny of the following were pres-
nt: contraindication to aspirin,
eparin, clopidogrel, stainless
teel, PTFE, or contrast media
hat could not be adequately
re-medicated; MI within 24 h
efore the procedure or any cre-
tine phosphokinase (CPK)-
yocardial band (MB) greater
han normal; left ventricular
jection fraction 25%; PCI in
nonstudy vessel required 24
before or during the index
rocedure or after (if staged pro-
edure earlier, all other entry
riteria must be met, including
ormal baseline creatine kinase-
B); unprotected left main disease; target lesion involving
he distal anastomosis; presence of a 50% untreated
tenosis proximal or distal to the target lesion; stent(s)
ocated within 5 mm of the target lesion borders; excessive
roximal tortuosity or lesion angulation; current participa-
ion in another investigational drug or device trial that had
ot completed the entire follow-up period; comorbidity
ith anticipated life expectancy to 12 months; liver
unction tests 3 normal; serum creatinine 2.0 mg/dl;
platelet count 100,000 cells/mm3; hemoglobin 10.0
/dl; history of stroke or transient ischemic attack within 6
onths; gastrointestinal bleeding within 6 months; history
f bleeding diathesis or coagulopathy or will refuse blood
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft surgery
CPK  creatine
phosphokinase
DES  drug-eluting stent(s)
IVUS  intravascular
ultrasound
PCI  percutaneous
coronary intervention
PTFE 
polytetrafluoroethylene
MB  myocardial band
MI  myocardial infarction
QCA  quantitative coronary
angiography
SVG  saphenous vein graft
TLR  target lesion
revascularization
TVF  target vessel failure
TVR  target vessel
revascularizationransfusions; and active pregnancy or lactation.
f
a
m
a
g
a
(
r
c
f
s
n
b
S
a
a
a
e
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 3 , 2 0 1 1
M A R C H 2 0 1 1 : 3 0 0 – 9
Stone et al.
PTFE Stent-Graft Randomized Trial
302Protocol and randomization. Direct stenting without pre-
dilation was not permitted. Before randomization, treat-
ment with any U.S. Food and Drug Administration-
approved distal protection and/or thrombectomy device was
permitted at the discretion of the operator, followed by
pre-dilation with an undersized balloon catheter. If all
eligibility criteria were present after pre-dilation, patients
were randomized 1:1 in open-label fashion to the
JOSTENT versus any U.S. Food and Drug Adminis-
tration-approved BMS. Randomization was performed in
random blocks of 4 to 6, stratified by the prior use of distal
protection and/or thrombectomy. For patients randomized
to the JOSTENT, the device was implanted at a nominal
pressure, after which post-dilation with a noncompliant
balloon was mandatory at a 1 to 1.1:1 balloon/artery ratio, to
18 atm. The JOSTENT was pre-mounted and available
in lengths ranging from 9 to 29 mm and in diameters
ranging from 3.0 to 5.0 mm. Only 1 JOSTENT was
intended for a single lesion, by intent; however, additional
JOSTENTs were permitted as necessary to treat residual
diseased segments or edge dissections. The BMS were
implanted according to standard of care.
Before the procedure patients received aspirin 325 mg,
and clopidogrel 300 mg was recommended. Procedural
anticoagulation was achieved with intravenous heparin, with
the activated clotting time maintained at 300 s (200 to
250 s, if a glycoprotein IIb/IIIa inhibitor was used per
investigator discretion). After the procedure all patients
were administered aspirin 325 mg daily indefinitely. Pa-
tients who received a JOSTENT were administered clopi-
dogrel 75 mg daily for at least 8 months, whereas clopi-
Figure 1. The JOSTENT Coronary Stent Graft
The JOSTENT coronary stent graft (Jomed GmbH, Rangendingen, Germany)
combines 2 laser-cut 316L slotted-tube balloon-expandable stainless steel
stents with polytetraﬂuoroethylene graft material. The polytetraﬂuoroethyl-
ene material is wrapped around the inner stent (approximately 2.5) and
sandwiched between the 2 stents.dogrel was recommended for at least 1 month in patients Streated with BMS. The CPK and CPK-MB levels were
measured at baseline and every 8 h 3 within 24 h after the
procedure. An electrocardiogram was obtained at baseline,
immediately after the procedure, at discharge, and addition-
ally for any recurrent symptoms.
Clinical follow-up visits were planned at the time of
discharge, 1 month, 8 months, 9 months, 12 months, and
then yearly through 5 years. In addition, follow-up angiog-
raphy was planned in all patients at 8 months after dis-
charge, unless angiography performed before 8 months
showed restenosis of the target lesion.
Data management. Study monitors verified all case report
orms data on-site. Major adverse cardiac events were
djudicated by an independent committee blinded to treat-
ent allocation. Quantitative coronary angiography (QCA)
nalyses were performed at an independent core angio-
raphic laboratory by technicians blinded to treatment
ssignment and clinical outcomes as previously described
18). Intravascular ultrasound (IVUS) guidance was not
equired but, if performed, was analyzed at an independent
ore ultrasound laboratory.
End points and deﬁnitions. The primary end point was the
rate of binary angiographic restenosis in the target lesion
at 8 months, defined as a 50% diameter stenosis within
the stent or the 5-mm proximal or distal stent margins.
The secondary end point was target vessel failure (TVF)
at 9 months, defined as the composite of all-cause death,
MI, or clinically driven TVR. Myocardial infarction was
diagnosed by a rise of CPK-MB to 3 normal. Target
vessel revascularization was defined as repeat PCI or
CABG of the target lesion (TLR) or vessel (TVR)
containing the target lesion and was considered clinically
driven if signs or symptoms of ischemia were present
referable to the target vessel with an in-lesion diameter
stenosis 50% by QCA or with an in-lesion diameter
stenosis 70% by QCA in the absence of ischemia. Stent
thrombosis was defined as thrombus or subacute closure
within the stented vessel at the time of a clinically driven
angiographic repeat study for documented ischemia or
any death not attributed to a noncardiac cause within the
first 30 days in the absence of documented angiographic
stent patency.
Sample size and statistical analysis. One hundred eighty-
our patients/arm would provide 90% power to demonstrate
uperiority with a 2-sided   0.05, on the basis of published
onrandomized data with the JOSTENT (14)—assuming a
inary restenosis rate at 8 months after BMS of 35% from the
AVED (Saphenous Vein De Novo) trial (8) and anticipating
reduction in restenosis to 20%. Two hundred fifty patients/
rm (500 total) were planned for enrollment, assuming an
ngiographic follow-up rate of 75%.
Categorical data were compared by chi-square or Fisher
xact tests. Continuous data were expressed as mean 
D and compared by unpaired t tests. Lesion level
m
t
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303variables, whether continuous or categorical, were com-
pared with Generalized Estimating Equations to accom-
modate correlated data. Adverse event analyses were
performed with time-to-event data, are displayed with
Kaplan-Meier methodology, and were compared with the
log-rank test. All data are presented in the intent-to-treat
population, consisting of all patients randomized, regard-
less of treatment actually received. A p value of 0.05 was
required for statistical significance. Statistical analyses
were performed by SAS (version 9.1, SAS, Cary, North
Carolina).
Results
Patients and procedures. Between August 9, 2001 and
August 28, 2003, 243 patients were randomized at 38 U.S.
centers. The manufacturer Jomed was acquired by Abbott
Vascular in August 2003, after which the trial was sus-
pended for performance of a futility analysis. It was deter-
mined, on the basis of this analysis, that the trial would not
be positive, and the study was terminated. Follow-up
continued, however, for the full 5 years for all randomized
patients.
The baseline demographic and clinical characteristics
were well matched between the 2 groups (Table 1). As
shown in Table 2, mean graft age was 10 years; 90% of
Table 1. Baseline Characteristics and Medication Us
(
Age (yrs) 6
Male
Current smoker
Diabetes mellitus
Hypertension
Hypercholesterolemia 1
Prior myocardial infarction 49
Prior percutaneous coronary intervention 64
Prior coronary artery bypass graft surgery 1
Prior stroke or transient ischemic attack
Prior congestive heart failure
Canadian Cardiovascular Society class III/IV
Left ventricular ejection fraction (%) 5
Aspirin use
Discharge 1
8 months 101
9 months 101
Thienopyridine use
Discharge 1
8 months
9 monthsValues are mean SD or n (%).lesions arose from the body of the SVG. Multiple SVG
lesions were treated in 23% of patients. Distal protection
devices were used in 43% of cases, and thrombectomy was
rarely used. The maximal stent implantation pressure was
significantly higher for the JOSTENT than for BMS.
Aspirin use was high in both arms throughout the study.
Thienopyridine use was more frequent in the JOSTENT
group at 8- and 9-month follow-up (Table 1).
Angiographic results. The baseline angiographic measures
in the 2 groups were well matched, except that the
reference vessel diameter in the BMS group was slightly
larger (Table 3). After PCI, the rates of Thrombolysis In
Myocardial Infarction flow and angiographic complica-
tions were comparable in the 2 groups. At 8-month
follow-up, late loss and the rates of binary restenosis and
vessel occlusion were not statistically different between
the JOSTENT and BMS groups (Table 3). The primary
end point of in-lesion binary restenosis occurred in 31.8%
of lesions treated with the JOSTENT versus 28.4% of
lesions treated with BMS (relative risk: 1.12, 95% CI:
0.72 to 1.75, p  0.63).
IVUS. Intravascular ultrasound after PCI was performed in
23 JOSTENT patients and 11 BMS patients. The minimal
luminal area was comparable in both groups (8.61  3.27
m2 vs. 8.76  3.63 mm2, respectively, p  0.91), as was
he average reference lumen area (11.83  4.66 mm2 vs.
11.27  3.86 mm2 respectively, p  0.73).
NT
15)
Bare-Metal Stent
(n  128) p Value
9.7 68.8 8.9 0.46
3%) 108 (84.4%) 0.22
3%) 18/127 (14.2%) 0.50
3%) 54 (42.2%) 0.53
3%) 107 (83.6%) 0.87
9%) 117 (91.4%) 0.46
3.0%) 63/125 (50.4%) 0.25
6.1%) 64 (50.0%) 0.34
%) 128 (100%) —
8%) 20 (15.6%) 0.86
8%) 26 (20.3%) 0.26
9%) 49 (38.3%) 0.68
2.5 49.3 12.5 0.48
3%) 128 (100.0%) 0.22
3.5%) 110/124 (88.7%) 0.20
3.5%) 108/124 (87.1%) 0.10
3%) 125 (97.7%) 1.0
7%) 77 (60.2%) 0.01
8%) 72 (56.3%) 0.06e
JOSTE
n  1
7.9
90 (78.
13 (11.
44 (38.
97 (84.
08 (93.
/114 (4
/114 (5
15 (100
17 (14.
17 (14.
47 (40.
0.5 1
13 (98.
/108 (9
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13 (98.
87 (75.
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304Clinical outcomes. After PCI, the peak CPK (106.2  107.1
U/l vs. 91.9  79.3 IU/l, p  0.26) and CPK-MB levels
(3.7 8.3 IU/l vs. 3.9 9.9 IU/l, p 0.84) were comparable
n the JOSTENT and BMS groups, respectively. Similarly,
here were no significant differences between groups in the
ates of MI, stent thrombosis, or other adverse events at 30
ays (Table 4). At 9 months, the major secondary end point of
VF occurred in 32.2% of patients treated with the
OSTENT versus 22.1% of patients treated with BMS (hazard
atio: 1.54, 95% CI: 0.94 to 2.53, p  0.08). Significant
ifferences between the 2 stents in the rates of any of the
omponents of TVF at 9 months were not apparent (Table 4).
Table 5 shows the annual rates of adverse cardiovascular
vents between 1 and 5 years. Events continued to accrue in
oth arms over time but more so in the JOSTENT arm,
uch that by 2 years and beyond TVF occurred more
requently in patients assigned to the JOSTENT. At the
nd of the 5-year follow-up period, TVF had occurred in
8.3% of patients treated with the JOSTENT versus
1.8% of patients treated with BMS (hazard ratio: 95%
I: 1.59 1.13 to 2.23, p  0.007) (Fig. 2). This difference
as driven primarily by more rapidly increasing TLR rates
n JOSTENT-treated patients. Although there were no sta-
istically significant differences between the 2 stent types in
he rates of MI or stent thrombosis, target vessel occlusion
as noted more frequently in the JOSTENT arm during
Table 2. Procedural Data
JOSTE
(n  115 Patient
Number of vein grafts treated
1 109 (9
2 6 (5
Number of lesions treated
1 88 (7
2 25 (2
3 2 (1
Graft age (yrs) 10.2
Vein graft lesion location: aorto-ostial 13 (9
Vein graft lesion location: body 126 (9
Vein graft coronary artery distribution
Left anterior descending 30 (2
Right 45 (3
Left circumﬂex 64 (4
Glycoprotein IIb/IIIa inhibitors used 63 (5
Distal protection used 48 (4
Thrombectomy used 2/114 (1
Total number of stents 1.37
Total stent length (mm) 20.7
Maximum device size (mm) 4.0
Maximum inﬂation pressure (atm) 18.5
Values are n (%) or mean SD.ong-term follow-up.iscussion
The present study was designed to overcome several poten-
tially important limitations from prior randomized trials of
the JOSTENT PTFE stent-graft in diseased SVGs. Nota-
bly, the JOSTENT—consisting of 2 balloon-expandable
stents containing a PTFE membrane—is frequently under-
expanded unless high-pressure inflations are performed
(19), which was not mandated in previous studies. More-
over, it has been hypothesized that delayed endothelializa-
tion of the PTFE material might explain the observed
tendency toward thrombotic occlusion of the JOSTENT.
Because prior studies required dual antiplatelet therapy for
only 1 to 3 months (15,16), a more prolonged course might
result in greater long-term graft patency. Finally, follow-up
was truncated at 6 to 12 months in earlier trials (15,16), a
duration insufficient to characterize the late prognosis after
SVG intervention (17).
In the present trial, high-pressure (18 atm) inflations
were performed in the JOSTENT with noncompliant
balloons; dual antiplatelet therapy was prescribed for 8
months; and follow-up was continued for 5 years. None-
theless, recruitment in the trial was terminated after
enrollment of approximately 50% of the planned sample
size for futility. The 8-month rates of late loss and
restenosis were not superior to BMS (with high resteno-
Lesions)
Bare-Metal Stent
(n  128 Patients, 154 Lesions) p Value
119 (93.0%) 0.56
9 (7.0%) 0.56
99 (77.3%) 0.88
28 (21.9%) 0.98
1 (0.8%) 0.60
9.5 5.3 0.26
17 (11.0%) 0.63
137 (89.0%) 0.63
26 (16.9%) 0.31
57 (37.0%) 0.41
71 (46.1%) 0.99
62 (48.4%) 0.31
55/127 (43.3%) 0.81
1/127 (0.8%) 0.60
1.36 0.61 0.97
21.8 13.0 0.36
4.0 0.7 0.97
15.3 3.3 0.0001NT
s, 139
4.8%)
.2%)
6.5%)
1.7%)
.7%)
5.1
.4%)
0.6%)
1.6%)
2.4%)
6.0%)
4.8%)
1.7%)
.8%)
0.65
7.3
0.6
2.9sis rates observed in both groups), even though angiog-
Myocar
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305raphy and IVUS demonstrated adequate stent expansion
of the JOSTENT. Although IVUS was not performed at
follow-up, these data suggest that either the porous
PTFE membrane is not sufficiently restrictive to prevent
neointimal hyperplasia from accumulating within the
lumen or restenosis might also arise from circulating cellular
mechanisms (20,21). Chronic recoil of the JOSTENT as an
alternate mechanism in selected patients cannot be excluded
without follow-up IVUS. Whether the trend toward in-
Table 3. Quantitative Coronary Angiography
Vessel-level analysis
Baseline (n 
TIMI ﬂow grade: 0/1
TIMI ﬂow grade: 2
TIMI ﬂow grade: 3
Immediate post-PCI (n 
TIMI ﬂow grade: 0/1
TIMI ﬂow grade: 2
TIMI ﬂow grade: 3
8-month follow-up (n
TIMI ﬂow grade: 0/1
TIMI ﬂow grade: 2
TIMI ﬂow grade: 3
Lesion-level analysis
Baseline (n 
Reference vessel diameter (mm)
Minimal luminal diameter (mm)
Diameter stenosis (%)
Lesion length (mm)
Immediate post-PCI (n 
Reference vessel diameter (mm)
Minimal luminal diameter, in-stent (mm)
Diameter stenosis, in-stent (%)
Minimal luminal diameter, in-lesion (mm)
Diameter stenosis, in-lesion (%)
Thrombus
No reﬂow
Dissection 2
Distal embolization
8-month follow-up (n
Reference vessel diameter (mm)
Minimal luminal diameter, in-stent (mm)
Diameter stenosis, in-stent (%)
Late loss, in-stent (mm)
Binary restenosis, in-stent
Minimal luminal diameter, in-lesion (mm)
Diameter stenosis, in-lesion (%)
Late loss, in-lesion (mm)
Binary restenosis, in-lesion
Values are n (%) or mean SD.
PCI percutaneous coronary intervention; TIMI Thrombolysis Increased late vessel occlusion with the JOSTENT is due tothrombosis or progressive hyperplasia also cannot be an-
swered by this study, although it is clear that the 8-month
use of dual antiplatelet therapy in most patients was insuf-
ficient to extend stent-graft patency.
The present study is the first to systematically follow all
patients for 5 years after SVG intervention. In this regard,
long-term follow-up serves to emphasize the bleak progno-
sis that can be expected after PCI of diseased SVGs with
either the JOSTENT or BMS. Five years after treatment
NT Bare-Metal Stent p Value
vessels) (n  132 vessels)
.7%) 7 (5.3%) 0.18
5.3%) 13 (9.8%) 0.20
3.1%) 112 (84.8%) 0.70
vessels) (n  132 vessels)
.8%) 3 (2.3%) 0.62
.8%) 1 (0.8%) 1.0
8.3%) 128 (97.0%) 0.69
essels) (n  90 vessels)
6.0%) 8 (8.9%) 0.16
.0%) 3 (3.3%) 1.0
0.0%) 79 (87.8%) 0.17
lesions) (n  130 lesions)
0.64 3.48 0.68 0.03
0.58 1.27 0.59 0.27
15.5 63.8 13.8 1.0
6.5 11.8 6.9 0.94
lesions) (n  130 lesions)
0.61 3.54 0.71 0.06
0.53 3.34 0.61 0.67
12.5 4.5 12.5 0.02
0.58 2.99 0.60 0.33
8.0 15.0 9.6 0.18
.4%) 1 (0.8%) 0.36
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306patients; MI, stent thrombosis, and vessel occlusion had
occurred in 17.4%, 5.6%, and 7.8% of patients, respectively;
TLR and TVR were required in 29.6% and 33.3% of
patients, respectively; and 22.3% of patients had died. Five
years after treatment with the JOSTENT, TVF had oc-
curred in more than two-thirds of patients, with worse
outcomes in every component measure compared with
BMS. Use of the stent-graft also did not prevent acute
angiographic complications such as distal embolization or
periprocedural MI. Lower pressure inflations or less ag-
gressive implantation technique might have prevented
complications from the “toothpaste” effect but would
likely have negatively affected late outcomes. Freedom
from early thrombosis or late occlusion was not enhanced
in a prior study by adding a heparin coat to the
JOSTENT (22). A different, totally encapsulated PTFE
stent-graft has similarly failed to prevent periprocedural
complications or late restenosis after SVG intervention
(23). Clearly, novel strategies are required for diseased
SVGs. Registry studies have suggested that DES might
be more efficacious than BMS (24,25), although the 2
Table 4. Clinical Outcomes at 30 Days and 9 Months
JOS
(n 
30-day events
Target vessel failure 8.7
Death, all-cause 0.9
Myocardial infarction 7.0
Q-wave 2.6
Non–Q-wave 4.3
Target vessel revascularization 0.9
Percutaneous coronary intervention 0.9
Coronary artery bypass graft surgery 0
Stent thrombosis 1.7
9-month events
Target vessel failure 32.2
Death, all-cause 6.1
Cardiac 5.3
Noncardiac 0.9
Myocardial infarction 10.6
Q-wave 3.5
Non–Q-wave 7.0
Target lesion revascularization 15.6
Percutaneous coronary intervention 14.7
Coronary artery bypass graft surgery 0.9
Target vessel revascularization 21.8
Percutaneous coronary intervention 20.9
Coronary artery bypass graft surgery 0.9
Stent thrombosis 3.6
Event rates are Kaplan-Meier estimates (number of events). *Adjudica
ization.small randomized trials that have been completed to date din this population were inconclusive (9,10). Double-
stranded oligonucleotide E2F decoys to transcription
factors implicated in the upregulation of several genes
involved in neointimal hyperplasia have also failed to
prolong SVG patency (26). Pan-arterial CABG and
hybrid PCI/CABG procedures should be increasingly
employed to reduce the use of SVGs as bypass conduits.
Study limitations. Recruitment was stopped early after a
utility analysis. However, examination of the CIs around
he final clinical and angiographic end points provides
eassurance that a possible beneficial effect of the
OSTENT is unlikely to have been missed. IVUS guid-
nce during the index procedure was used in a minority of
atients, although it is uncertain whether acute proce-
ural results would have been improved with IVUS, given
he requirement to dilate all JOSTENTs to 18 atm
ith a noncompliant balloon. Only 76% of patients
andomized to the JOSTENT were adherent with dual
ntiplatelet therapy at 8 months. It is doubtful that the
esults would have been meaningfully different had clopi-
Bare-Metal Stent
(n  128) p Value
7.0% (9) 0.63
0.0% (0) 0.29
7.0% (9) 0.99
1.6% (2) 0.57
5.5% (7) 0.69
0.8% (1)† 0.94
0.8% (1) 0.94
0% (0) —
0.8% (1) 0.50
22.1% (27) 0.08
3.3% (4) 0.31
2.5% (3) 0.27
0.8% (1) 0.96
10.4% (13) 0.96
2.4% (3) 0.61
8.0% (10) 0.78
13.5% (16) 0.66
13.5% (16) 0.81
0.8% (1) 0.96
15.1% (18) 0.20
15.1% (18) 0.26
0.8% (1) 0.96
2.5% (3) 0.61
a cardiac death. †Each was adjudicated as a target lesion revascular-TENT
115)
% (10)
% (1)*
% (8)
% (3)
% (5)
% (1)†
% (1)
% (0)
% (2)
% (37)
% (7)
% (6)
% (1)
% (12)
% (4)
% (8)
% (17)
% (16)
% (1)
% (24)
% (23)
% (1)
% (4)
ted asogrel compliance been higher. Distal protection devices
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307were used in only 43% of enrolled patients, despite their
documented ability to reduce periprocedural emboliza-
tion and no reflow (6,7). This percentage, however, is
higher than their contemporary use in SVG intervention.
In this regard, although recruitment in this trial occurred
Table 5. Clinical Outcomes Annually Through 5 Years
JOSTENT
(n  115
Target vessel failure
1 yr 39.2% (45
2 yrs 51.6% (59
3 yrs 60.2% (68
4 yrs 63.1% (71
5 yrs 68.3% (76
Death, all-cause
1 yr 7.0% (8)
2 yrs 12.3% (14
3 yrs 18.8% (21
4 yrs 23.5% (26
5 yrs 29.8% (32
Myocardial infarction
1 yr 14.2% (16
2 yrs 18.9% (21
3 yrs 21.0% (23
4 yrs 22.2% (24
5 yrs 26.2% (27
Target lesion revascularization
1 yr 20.9% (23
2 yrs 32.1% (35
3 yrs 37.4% (40
4 yrs 39.8% (42
5 yrs 43.9% (45
Target vessel revascularization
1 yr 28.2% (31
2 yrs 36.6% (40
3 yrs 41.9% (45
4 yrs 44.2% (47
5 yrs 48.2% (50
Stent thrombosis
1 yr 5.4% (6)
2 yrs 7.3% (8)
3 yrs 8.3% (9)
4 yrs 9.5% (10
5 yrs 10.9% (11
Target vessel occlusion
1 yr 5.4% (6)
2 yrs 9.1% (10
3 yrs 11.2% (12
4 yrs 11.2% (12
5 yrs 14.0% (14
Event rates are Kaplan-Meier estimates (number of events).more than 7 years ago, the tools for and technique ofSVG PCI have not materially changed since then (other
than the availability of DES). Finally, only SVGs with
discrete (25 mm long) lesions were enrolled in the
present trial. The long-term outcomes in both arms
would likely have been even worse had severely degener-
Bare-Metal Stent
(n  128) p Value
28.0% (34) 0.07
33.3% (40) 0.008
37.0% (44) 0.001
46.0% (53) 0.006
51.8% (59) 0.007
5.0% (6) 0.51
9.4% (11) 0.47
11.2% (13) 0.13
17.2% (19) 0.22
22.3% (24) 0.20
11.3% (14) 0.53
13.1% (16) 0.27
14.1% (17) 0.21
16.2% (19) 0.27
17.4% (20) 0.16
16.9% (20) 0.46
19.7% (23) 0.06
21.8% (25) 0.02
26.2% (29) 0.04
29.6% (32) 0.04
21.1% (25) 0.22
23.8% (28) 0.05
26.8% (31) 0.03
31.2% (35) 0.04
33.3% (37) 0.04
3.4% (4) 0.44
3.4% (4) 0.20
3.4% (4) 0.13
5.6% (6) 0.24
5.6% (6) 0.16
1.6% (2) 0.12
3.5% (4) 0.08
3.5% (4) 0.03
6.9% (7) 0.18
7.8% (8) 0.13)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)ated or occluded SVGs been included (27).
tion)
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308Conclusions
The present trial underlines the dismal long-term prognosis
of patients with diseased SVGs requiring PCI. Polytetra-
fluoroethylene-covered stent-grafts have a greater failure
rate when used for this application than BMS and,
therefore, should be reserved for life-threatening perfo-
rations of the coronary vasculature (12). The results of
this study also emphasize the need for breakthrough
strategies to prevent and treat SVG degeneration or
preferably revascularization approaches that involve leaving
saphenous veins undisturbed in the legs whenever possible.
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APPENDIX
For a list of the BARRICADE trial organization and participating sites and
investigators, please see the online version of this article.
